Phaseline

Companies › Shine-On Biomedical

Shine-On Biomedical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SOB100
HLA-G targeted exosome with anti-HLA-G VHH nanobody
HLA-GPhase 1Healthy SubjectsDec 2026
SOA101
Nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3
CD274, HLA-G, CD3EPhase 1Solid TumorsFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07219940SOB100Phase 1Healthy SubjectsOtherDec 2026
NCT07055594SOA101Phase 1Solid TumorsOncologyFeb 2028

Targets

HLA-G (2) CD274 (1) CD3E (1)

Companies with the same targets

Johnson & Johnson (Janssen) AstraZeneca Roche Pfizer Amgen Shanghai Chia Tai Tianqing Pharmaceutical Technology Development IO Biotech Genmab Regeneron Pharmaceuticals Tizona Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.